Iowa Medicaid spending on GLP-1 drugs

How much did Iowa Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $87.4 million for GLP-1 drugs paid through Iowa Medicaid in 2025, across at least 88,518 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 83 rows of 227, so these figures are floors.

Pharmacies were reimbursed at least $20.2 million for GLP-1 drugs paid through Iowa Medicaid in 2026 (quarter 1 only, as posted so far), across at least 19,750 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 32 rows of 67, so these figures are floors.

By year and ingredient

2020at least $11,242,081No dataat least $4,836,182at least $1,151,246at least $2,394,366at least $35,978at least $36,312at least $19,696,165
2021at least $13,049,496No dataat least $5,787,704at least $10,895,572at least $1,755,884$77,632$57,100at least $31,623,387
2022at least $13,864,658at least $669,115at least $5,738,351at least $25,278,344at least $892,755at least $54,202at least $13,711at least $46,511,136
2023at least $27,430,476at least $5,886,617at least $3,763,865at least $25,876,162at least $464,734SuppressedSuppressedat least $63,421,854
2024at least $41,450,121at least $9,337,957at least $1,025,515at least $14,194,679at least $122,109SuppressedSuppressedat least $66,130,382
2025at least $52,266,504at least $23,615,176at least $331,481at least $11,137,205at least $12,747SuppressedNo dataat least $87,363,112
2026 (Q1)at least $11,053,126at least $7,242,970at least $11,941at least $1,937,749No dataSuppressedNo dataat least $20,245,786

By product, 2025

Ozempicat least $50,127,217at least 51,8081 of 25
Rybelsusat least $850,730at least 8661 of 13
Wegovyat least $1,288,557at least 97112 of 32
Mounjaroat least $18,189,823at least 17,38720 of 45
Zepboundat least $5,425,353at least 5,11216 of 37
Liraglutide (generic name listing)at least $263,038at least 5487 of 22
Victozaat least $68,443at least 1124 of 10
Trulicityat least $11,137,205at least 11,69814 of 34
Bydureonat least $12,747at least 162 of 3
ByettaSuppressedSuppressed1 of 1
Exenatide (generic name listing)SuppressedSuppressed1 of 1
SoliquaSuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $18,738,701at least 19,19415 of 51
Q2 2025at least $21,255,947at least 21,59017 of 54
Q3 2025at least $23,036,982at least 23,25823 of 58
Q4 2025at least $24,331,483at least 24,47628 of 64

By quarter, 2026 (posted so far)

Q1 2026at least $20,245,786at least 19,75032 of 67

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.